Skip to content

A retrospective study of the safety and efficacy of ALPPS versus TACE in the treatment of liver cancer

A retrospective study of the safety and efficacy of ALPPS versus TACE in the treatment of liver cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075426
Enrollment
Unknown
Registered
2023-09-05
Start date
2023-09-05
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hepatic carcinoma

Interventions

ALPPS group:NA

Sponsors

The First Affiliated Hospital of PLA Army Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with primary liver cancer and initially treated (2) Insufficient liver volume remaining after direct surgical resection of the tumor (FLR < 40% in cirrhosis and < 30% in non-cirrhosis) (3) ALPPS and TACE were the main surgical methods (4) Complete clinical data

Exclusion criteria

Exclusion criteria: (1) Cholangiocarcinoma, metastatic liver cancer and other non-HCC patients (2) History of liver cancer treatment before surgery (3) Extensive tumor metastasis (4) Patients allergic to iodized contrast agents were also excluded (5) The interval between the first and second operations was more than 6 months (6) Clinical data are not complete

Design outcomes

Primary

MeasureTime frame
Overall 1-year and 3-year survival rates were measured in the ALPPS group and the matched TACE group;

Secondary

MeasureTime frame
The incidence of complications within 30 days after operation in ALPPS group was analyzed;

Countries

China

Contacts

Public ContactLeida Zhang

The First Affiliated Hospital of PLA Army Medical University

2518569931@qq.com+86 135 0832 0249

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026